Company Profile

Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company’s mission to combat diseases by identifying and exploiting their unique vulnerabilities.


Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... (more)

Stock Performance

NASDAQ: ACHN

Press Releases  [View all]

Mar 8, 2018
Achillion to Present at the Barclays Global Healthcare Conference

Feb 28, 2018
Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018

Feb 26, 2018
Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy

Feb 22, 2018
Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results

Feb 9, 2018
Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Financial Disclosures  [View all]

Fourth Quarter Financial Results
Feb 22, 2018
Annual Report (10-K)
Apr 20, 2018
Proxy Statement (DEF 14A)
Nov 1, 2017
Quarterly Report (10-Q)
Aug 8, 2017
Quarterly Report (10-Q)
May 4, 2017
Quarterly Report (10-Q)